Current Clinical Trials | ECHO Associates

A Beacon of Light on Your Cancer Care Journey


Current Trials

ECHO Open to Acrrual Clinical Trials

Updated: 10/18/21

Bladder / Urothelial

SGN22E-002 / EV-103
A Study of enfortumab vedotin (ASG-22CE) as monotherapy or in combination with other anticancer therapies for the treatment of urothelial cancer

SGN22E-003 / EV-302
An open-label, randomized, controlled phase 3 study of Enfortumab Vedotin in combination with Pembrolizumab with or without chemotherapy, versus chemotherapy alone in previously untreated locally advanced or metastatic urothelial cancer.



NRG-GI004 / SWOG-S1610 *Temperarily Closed*
Colorectal Cancer Metastatic dMMR Immuno-Therapy (COMMIT) Study: A Randomized Phase III Study of mFOLFOX6 / Bevacizumab Combination Chemotherapy with or without Atezolizumab or Atezolizumab Monotherapy in the First-Line Treatment of Patients with Deficient DNA Mismatch Repair (dMMR) Metastatic Colorectal Cancer

MRT 849-010 / Krystal-10
A Randomized Phase 3 Study of MRTX849 in Combination with Cetuximab Versus Chemotherapy in Patients with Advanced Colorectal Cancer with KRAS G12C Mutation with Disease Progression On or After Standard First-Line Therapy


A Phase II, Open-Label Study of Encorafenib + Binimetinib in Patients with BRAFv600E-Mutant Non-Small Cell Lung Cancer

JZP 712-402
Emerge 402: Phase IV Observational Study to Collect Safety and Outcome ata in Real-World Setting in Adult Patients with Extensive Stage Small Cell Lung Cancer (SCLC) Receiving Zepzelca

Alchemist Trials Adjuvant Trials for completely resected patients EGFR or ALK positive

Adjuvant Lung Cancer enrichment marker identification and sequencing trial (Alchemist)

D910LC00001 MERMAID-1
A phase III, Randomized, Multicenter, Double-blind, Placebo-controlled study to determine the efficacy of Adjuvant Durvalumab in combination with Platinum-based Chemotherapy in completely Resected Stage II-III NSCLC (mermaid-1)

D910MC00001 MERMAID-2
A Phase III, Randomized, Multicenter, Double-blind, Placebo-controlled Study of Durvalumab for the Treatment of Stage II-III NSCLC patients with Minimal Residual Disease Following Surgery and Curative Intent Therapy

A phase III double-blind trial for surgically resected early stage Non-Small Cell Lung cancer: Crizotinib versus Placebo for pateints with tumors harboring the Anaplastic Lymphoma Kinase (ALK) fusion protein

First Line Metastatic

GSK 213400
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study comparing Niraparib plus Pembrolizumab versus Placebo plus Pembrolizumab as maintenance Therapy in participants whose disease has remained stable or responded to First-Line Platinum-Based Chemotherapy with Pembrolizumab for Stage IIIB or IV Non-Small Cell Lung Cancer (Zeal-1L)

Mirati 849-007
A Phase 2 Trial of MRTX849 in Combination with Pembrolizumab in Patients with Advanced non-Small Cell Lung Cancer with KRAS G12C Mutation

A multicenter, open label, single-arm phase II study to evaluate anti-tumor efficacy and safety of NT-17 (efineptakin alfa) in combination with atezolizumab in subjects with previously untreated, PD-L1 expressing, locally advanced or metastatic non-small cell lung cancer

A Randomized Phase 3 Multicenter Open-Label Study to Compare the Efficacy of TAK-788 as First-Line Treatment Versus Platinum-Based Chemotherapy in Patients with Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutation

Second Line Metastatic

GSK 213410
A Randomized, Open Label Phase 2/3 Study Comparing Cobolimab + Dostarlimab + Docetaxel to Dostarlimab + Docetaxel to Docetaxel Alone in Participants with Advanced Nonsmall Cell Lung Cancer who have Progressed on Prior Anti PD (L)1 Therapy and Chemotherapy (Costar Lung)

Mirati MRT516-005
A Randomized Phase 3 Study of Sitravatinib in Combination with Nivolumab versus Docetaxel in Patients with Advanced Non-Squamous Non-Small Cell Lung Cancer with Disease Progression on or after Platinum-Based Chemotherapy in Combination with Checkpoint Inhibitor Therapy


D8227C00001 / ACE-LY-312 / Escalade
A phase 3, Randomized, Double-Blind, Placebo-controlled study of Acalabrutinib in combination with Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Subjects 65 years or younger with previously untreated Non-Germinal Center Diffuse Large B-Cell Lymphoma

Prostate Cancer

64091742PCR0002 / TIME / Prevalence
Biomarker Study to Determine Frequency of DNA-repair Defects in Men with Metastatic Prostate Cancer


A Phase I/II Dose-Escalation and Efficacy Study of LAE001/Prednisone plus Afuresertib in Patients with Metastatic Castration-Resistant Prostate Cancer Following Standard of Care Treatment

A Phase II-III trial of Adjuvant Radiotherapy and Androgen Deprivation Following Radical Prostatectomy with or without Adjuvant Docetaxel

Solid Tumors

An Open-Label Phase II Study Evaluating Targeted Therapies in Patients Who Have Advanced Solid Tumors with Genomic Alterations or Protein Expression Patterns predictive of response

Open-Label Phase 2 Study of Ladiratuzumab Vedotin (LV) for Unresectable Locally Advanced or Metastatic Solid Tumors


Lung Screening

International Early Lung Cancer Action Program: Enrollment and Screening Protocol

Supportive Care

Blue Note / PROT001
Double-blinded, randomized, controlled, adaptive trial to compare effectiveness of two digital software medical devices (attuneTM and cerenaTM) as interventions for physical and emotional health in adjunctive oncology treatment, in order to determine relative impact on anxiety and depressive symptoms in stage I-III breast cancer and stage I-III non-small cell lung cancer participants.

Ready 1 / CUSA-081-HEM-01 /YYA36723
Phase 3, Randomized, Double-Hem-Blind, Active and Placebo Controlled Study on the use of CUSA-081 for Dysfunctional Central Venous Access Devices (CVADs)

Seer – 020102 (SeerPro)
A Prospective Blood Sample Collection Study to Evaluate a Panel of Protein-based Biomarkers

Exact Sciences Thrive LLC / Detecting Cancers Earlier Through Elective Plasma-Based CancerSEEK Testing – Ascertaining Serial Cancer Patients to Enable New Diagnostic II (DETECT-ASCEND 2)

For more information on clinical trials, please contact: Dr. Susan Johnson, Director of Research or 860-886-8362.